Apnimed, Inc. (APMD) Stock

NASDAQ: APMDHealthcare company in the biotechnology industry, based in Cambridge, MA.

Apnimed stock price chart

APMD interactive chart →

APMD stock quote & key statistics

Apnimed earnings per share

Income →
Earnings per share

Apnimed revenue & net income

Income →
RevenueNet income

Apnimed annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$38.5M-$932,000—
FY2024$8.0M-$111.3M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Apnimed, Inc.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Apnimed stock FAQ

What is the Apnimed stock ticker symbol?

Apnimed, Inc. trades on the NASDAQ under the ticker symbol APMD.

What sector and industry is Apnimed in?

Apnimed, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Apnimed have?

Apnimed, Inc. has about 81 full-time employees.

What were Apnimed's revenue and earnings last fiscal year?

Apnimed reported revenue of $38.5M and net income of -$932,000 in fiscal 2025. Revenue grew 380.1% from the prior year.

Is Apnimed in the Russell 2000?

Yes. Apnimed, Inc. (APMD) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Apnimed go public?

Apnimed stock began trading on July 31, 2026.

Russell 2000 Biotechnology stocks

All Russell 2000 →